3del Zoppo GJ, Higashida RT. Furlan AJ. etal, PROACT: a phase Ⅱ randomized trial of recombinant pro urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism, Stroke, 1998, 29(6):4-11
4Hacke W. Kaste M. Fieschi C, et al. Randomised double blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS Ⅱ), Lancet, 1998, 352 (9136):1245-1251
5Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute iscbemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke, 1998, 29: 18-22
6Davenport R. Dennis M. Neurological emergencies: acute stroke. J Neurol Neurosurg Psychiatry, 2000. 68 (3): 277-288
7Cocho D, Belvis R, Marti-Fabregas J, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology, 2005, 64:719-20
8Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology, 2001, 56 (8):1015-20
9Linda SW, Askiel B. D Orinda R, et al, Stroke patients' knowledge of stroke, Stroke,1997, 28(5): 912-915
10Juan CG, Ana PE, Eva F, et al. Analysis of the reasons for exclusion from tPA therapy after early arrival in acute stroke patients. Clinical Neurology and Neurosurgery, 2007,109 (1): 50-53
